DLG EXPO(SH:600826)2022-04-25 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 40,022,379.50, representing a decrease of 37.33% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 80,467,558.31, with a net profit excluding non-recurring items of CNY -43,417,832.45[5]. - The company reported a net loss for Q1 2022, with total operating income not covering total operating costs, leading to a negative operating margin[26]. - The company reported a net loss of ¥85,454,510.07 for Q1 2022, compared to a net loss of ¥51,048,244.71 in Q1 2021, representing an increase in loss of approximately 67.3% year-over-year[27]. - Operating profit for Q1 2022 was a loss of ¥99,021,130.93, worsening from a loss of ¥54,860,701.30 in the same period last year[27]. - Total comprehensive loss amounted to ¥191,778,690.90 in Q1 2022, compared to a loss of ¥134,364,246.25 in Q1 2021, indicating a year-over-year increase of about 42.7%[27]. - Total revenue from sales of goods and services was ¥110,124,688.43 in Q1 2022, a decline of 39% from ¥180,690,446.66 in Q1 2021[29]. - The company incurred a total operating expense of ¥250,039,519.81 in Q1 2022, which is an increase from ¥238,396,055.07 in Q1 2021[29]. Cash Flow and Assets - The net cash flow from operating activities was CNY -122,659,711.70, indicating significant cash outflow[5]. - Cash and cash equivalents were CNY 874,686,811.02 as of March 31, 2022, compared to CNY 1,136,415,846.70 as of December 31, 2021, a decline of 23.1%[22]. - The company generated operating cash flow of ¥127,379,808.11 in Q1 2022, down 46.4% from ¥237,524,422.23 in Q1 2021[29]. - Cash flow from investing activities showed a net outflow of ¥136,919,240.27 in Q1 2022, compared to a net outflow of ¥16,351,651.68 in Q1 2021, reflecting a significant increase in investment expenditures[30]. - Total current assets decreased to CNY 2,262,104,221.80 in Q1 2022 from CNY 2,618,412,756.80 in Q1 2021, a reduction of 13.6%[23]. - Total non-current assets increased to CNY 2,668,288,767.02 in Q1 2022 from CNY 2,603,960,108.71 in Q1 2021, an increase of 2.5%[23]. - Cash and cash equivalents at the end of Q1 2022 were ¥824,610,928.87, down from ¥1,077,345,821.41 at the end of Q1 2021, a decrease of approximately 23.5%[30]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 18,771[9]. - The largest shareholder, Shanghai Lansheng (Group) Co., Ltd., held 41.17% of the shares[10]. - Shareholders' equity attributable to the parent company decreased by 5.03% to CNY 3,529,162,240.25[6]. - Total equity decreased to CNY 3,600,528,168.61 in Q1 2022 from CNY 3,792,306,859.51 in Q1 2021, a decrease of 5%[25]. Operational Challenges - The company reported a significant impact on its business revenue due to the ongoing COVID-19 pandemic, which has led to a continuous halt in its exhibition business since early 2022[12]. - The company has faced significant operational challenges due to the pandemic, which is expected to adversely affect its financial condition and operating results for the entire year of 2022[12]. - The company experienced a 31.72% reduction in operating costs, attributed to the impact of the pandemic[7]. - The company has actively participated in pandemic prevention efforts, converting the Shanghai Expo Exhibition Center into a makeshift hospital to support over 7,000 patients during peak times[13]. - The company has formed a management team of 76 employees to coordinate with over 300 construction personnel for the renovation and operational support of makeshift hospitals[13]. Corporate Actions - The company plans to terminate its A-share restricted stock incentive plan due to the adverse effects of the pandemic on its operational performance, which has made it difficult to meet expected targets[15]. - As of March 31, 2022, the company has repurchased a total of 3,159,840 shares, accounting for approximately 0.59% of its total share capital[16]. - The company has proposed to change the purpose of repurchased shares from "for stock incentive plans" to "for cancellation and corresponding reduction of registered capital"[16]. - The company is undergoing changes to its registered capital and business scope, with the total number of shares decreasing from 535,920,895 to 532,761,055 after the planned cancellation of repurchased shares[17]. - The company has revised its articles of association to reflect changes in registered capital and business scope, including the addition of medical device sales[17]. Accounts Receivable and Inventory - Accounts receivable decreased by 36.58%, indicating improved collection efforts[7]. - Accounts receivable decreased to CNY 56,052,491.81 in Q1 2022 from CNY 88,379,819.48 in Q1 2021, representing a decline of 36.5%[23]. - Inventory increased significantly to CNY 65,597,129.23 in Q1 2022, up 96% from CNY 33,509,600.87 in Q1 2021[23].